Research and Clinical Interests
Dr. Zolla-Pazner is an immuno-biologist who has devoted her professional life to areas of immunology where basic research intersects with the needs of modern medicine. Her doctoral research on the immunochemical analysis of antibody specificity has formed the foundation of her work, leading to studies of immunoregulation of B cells, tumor biology, molecular mimicry among proteins, analyses of protein structure/function relationships, and the prevention, treatment and diagnosis of infectious diseases. Her current work focuses on the development of an AIDS vaccine that will induce protective antibodies to HIV.
Agarwal A, Hioe CE, Swetnam J, Zolla-Pazner S, Cardozo T. Quantitative assessment of masking of neutralization epitopes in HIV-1. Vaccine. 2011 Jan 7;Cited in Pubmed; PMID 21216319. doi: 10.1016/j.vaccine.2010.12.052. PMCID: PMC3135678 [Available on 2012/7/7].
Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, Williams C, Seaman MS, Cardozo T, Gorny MK, Wang S, Lu S, Pinter A, Zolla-Pazner S. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology. 2010 Sep 30;405(2):513-23. Epub 2010 Jul 21. Cited in Pubmed; PMID 20663531. doi: 10.1016/j.virol.2010.06.027.
Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, Zolla-Pazner S, Kong XP. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol. 2010 Aug;17(8):955-61. Epub 2010 Jul 11. Cited in Pubmed; PMID 20622876. doi: 10.1038/nsmb.1861.
Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C, Gorny MK, Zolla-Pazner S. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One. 2010 Apr 21;5(4):e10254. Cited in Pubmed; PMID 20421997. doi: 10.1371/journal.pone.0010254. PMCID: PMC2858080.
Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. Structural Basis of Co-Receptor Selectivity by the HIV-1 V3 Loop. AIDS Res Hum Retroviruses. 2007;23:415–26. Cited in Pubmed; PMID 17411375.
Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Koning FA, Nadas A, Anyangwe C, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of HIV-1. J Virol. 2006;80:6865–72. Cited in Pubmed; PMID 16809292.
Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, Gorny MK, Zolla-Pazner S, Casadevall A, Goldstein H. Targeting killing of virally-infected cells by radiolabeled antibodies to viral proteins. PLoS Medicine. 2006;3:e427. Cited in Pubmed; PMID 17090209.
Gorny MK, Stamatatos L, Volsky B, Revesz K, Williams C, Wang XH, Cohen S, Staudinger R, Zolla-Pazner S. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol. 2005. 2005;79:5232–7. Cited in Pubmed; PMID 15795308.
Rosen O, Chill J, Sharon M, Kessler N, Mester B, Zolla-Pazner S, Anglister J. Induced Fit in HIV-Neutralizing Antibody Complexes: Evidence for Alternative Conformations of the gp120 V3 Loop and the Molecular Basis for Broad Neutralization. Biochemistry. 2005;44:7250–8. Cited in Pubmed; PMID 15882063.
Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov CP, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S. The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope. J Virol. 2004;78:2394–404. Cited in Pubmed; PMID 14963135.
Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK. The Cross-Clade Neutralizing Activity of a Human Monoclonal Antibody Is Determined by the GPGR V3 Motif of HIV Type 1. AIDS Res Hum Retroviruses. 2004;20:1254–8. Cited in Pubmed; PMID 15588347.
Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. Structural rationale for the broad neutralization of HIV-1 by human antibody 447-52D. Structure. 2004;12:193–204. Cited in Pubmed; PMID 14962380.
Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov CP, Pinter A, Zolla-Pazner S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize HIV-1 primary isolates from various clades. J Virol. 2002;76:9035–45. Cited in Pubmed; PMID 12186887.
Verrier F, Nadas A, Gorny MK, Zolla-Pazner S. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol. 2001;75:9177–86. Cited in Pubmed; PMID 11533181.
Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nadas A, Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol. 2000;74:7096–107. Cited in Pubmed; PMID 10888650.
Selected Books and Reviews
Zolla-Pazner S, Cardozo T. Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol. 2010 Jul;10(7):527-35. Cited in Pubmed; PMID 20577269. doi: 10.1038/nri2801.
Gorny MK, Zolla-Pazner S. Human monoclonal antibodies that neutralize HIV-1. In: Korber BTM, Brander C, Haynes BF, Koup R, Moore JP, Walker BD, Watkins DI, editors. HIV Molecular Immunology 2003. Los Alamos, N.M.: Los Alamos National Laboratory, Theoretical Biology and Biophysics; 2004. pp. 35–48.
Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nature Rev Immunol. 2004;4:199–210. Cited in Pubmed; PMID 15039757.
American Association of Immunologists; American Association for the Advancement of Science; American Society of Microbiology; New York Academy of Science; Clinical Immunology Society
Bill & Melinda Gates Foundation Grant Recipient (2006)
Pioneer Lecture: Immunology of AIDS, 2003 Keystone Conference, Banff (April 2003)
Sustained Superior Performance Award, Veterans Administration Medical Center (1990-1997)